Designing tracers for PET imaging of the urokinase-type plasminogen activator receptor from a cyclic uPA-derived peptide: first in vitro evaluations
The treatment of cancer remains a major challenge, especially after tumour cell dissemination and metastases formation. Expression of the urokinase-type plasminogen activation system including urokinase (uPA) and its receptor (uPAR) has been associated with the complex process of cell migration, a t...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
10 April 2019
|
| In: |
Journal of labelled compounds and radiopharmaceuticals
Year: 2019, Volume: 62, Issue: 8, Pages: 483-494 |
| ISSN: | 1099-1344 |
| DOI: | 10.1002/jlcr.3735 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/jlcr.3735 Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/jlcr.3735 
|
| Author Notes: | Anja Wacker, Ulrike Bauder‐Wüst, Martin Schäfer, Jana Schmidt, Yvonne Remde, Sven Stadlbauer, Matthias Eder, Christos Liolios, Klaus Kopka |
| Summary: | The treatment of cancer remains a major challenge, especially after tumour cell dissemination and metastases formation. Expression of the urokinase-type plasminogen activation system including urokinase (uPA) and its receptor (uPAR) has been associated with the complex process of cell migration, a tumour's invasive potential as well as a reduced overall and disease-free survival of patients with solid cancers and haematological disorders. A cyclic peptide cyclo[21,29][d-Cys21,Cys29]-uPA21-30 was designed from the growth factor-like domain (GFD) of urokinase whose binding to uPAR was found to inhibit tumour growth and spread of human ovarian cancer cells in mice. With the aim of visualising uPAR expression using PET imaging to attempt an estimate on the tumour's aggressiveness, the cyclic peptide was modified with an either C- or N-terminally attached variable spacer and chelator. The free ligands were evaluated for their binding affinities to the isolated human uPAR and labelled with 68Ga and 177Lu to assess their lipophilicities and stabilities in human serum. Although retaining the full binding potential displayed by cyclo[21,29][d-Cys21,Cys29]-uPA21-30 to its target was found to be a challenging task upon both C- and N-terminal modification, chelator-bearing ligands were identified that can serve as promising starting points in the development of uPAR-addressing PET tracers. |
|---|---|
| Item Description: | Gesehen am 08.04.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1099-1344 |
| DOI: | 10.1002/jlcr.3735 |